Feb. 25, 2025 – The FDA has approved a new treatment plan for a long-acting injection, making it easier for people with moderate to severe opioid use disorder (OUD) to start and keep up with ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

The FDA has approved updated labeling for Sublocade (buprenorphine extended-release) injection to include a rapid induction protocol and alternative injection sites.

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

Pharmaceutical giant Indivior said on Monday that the US Food and Drug Administration has approved label changes for its ...

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid ...

The US Food and Drug Administration (FDA) has approved label changes for Sublocade (buprenorphine extended-release), ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Indivior (INDV) announced that the FDA has approved label changes for Sublocade including a rapid initiation protocol and alternative injection ...